The PTC phase 2B trial on Duchenne muscular dystrophy (DMD) has closed. The 4 children participating from the Institute of Myology in the double blind protocol are thus part of the open study. They will receive the treatment that overrides the stop codon. This trial aims to assess whether the molecule PTC124 improves the ability to walk as well as the function and muscle strength, and if it is well tolerated by patients. The first results are expected between March and June 2010.
Références :